Browse
Submit Data
Databases
API
Help

Dataset Information

3 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

A poilot study of eribulin monotherapy in chemorefractory patients with BRAF V600E-mutant metastatic colorectal cancer

ABSTRACT: Interventions: Eribulin 1.4 mg/m2 days 1 and 8 (repeated every 21 days) Primary outcome(s): Objective response rate; ORR Study Design: Single arm Non-randomized

DISEASE(S): Colorectal Cancer

PROVIDER: 2642859 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

A multicenter phase II study of eribulin monotherapy in patients with BRAF V600E mutant metastatic colorectal cancer

Project description:Interventions: Eribulin is administered intravenously at a dose of 1.4mg/m^2/day on Days 1 and 8, repeated every 21 days. Primary outcome(s): Confirmed objective response rate(ORR) by investigators’ assessment Study Design: Single arm Non-randomized

| 2646378 | ecrin-mdr-crc

Triplet rechallenge of BEACON regimen for RAS wild-type and BRAF V600E mutant metastatic colorectal cancer

Project description:Interventions: Encorafenib 300 mg once daily Binimetinib 45 mg twice daily Cetuximab 400 mg/m^2 Day 1, 250 mg/m^2 Day 8, 15, 22 (250 mg/m^2 from Cycle 2 later) These treatments are repeated every 28 days in one cycle. Primary outcome(s): Objective Response Rate (ORR) as determined by the site-investigator Study Design: single arm study, open(masking not used), uncontrolled control, single assignment, treatment purpose

| 2614542 | ecrin-mdr-crc